Data on diabetic retinopathy patients showed those who received monthly ranibizumab treatment were more likely than those who received sham injections to attain improvements in vision and disease severity at three years. Researchers also found patients in the ranibizumab arm were three times less likely to develop proliferative diabetic retinopathy than those in the control group. The findings were presented at the American Society of Retina Specialists meeting.

Related Summaries